Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

122.25
+1.200.99%
Post-market: 122.250.00000.00%19:58 EDT
Volume:656.44K
Turnover:80.15M
Market Cap:13.22B
PE:269.48
High:123.44
Open:121.48
Low:120.56
Close:121.05
52wk High:123.44
52wk Low:28.66
Shares:108.10M
Float Shares:96.44M
Volume Ratio:0.88
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4537
EPS(LYR):0.8200
ROE:8.23%
ROA:0.47%
PB:18.72
PE(LYR):149.09

Loading ...

Hagens Berman Files Securities Class Action Against Corcept Therapeutics

Reuters
·
Mar 05

Canaccord Genuity Sticks to Its Buy Rating for Corcept Therapeutics (CORT)

TIPRANKS
·
Mar 04

Pomerantz Files Class Action Lawsuit Against Corcept Therapeutics

Reuters
·
Mar 04

Stock Track | Corcept Therapeutics Plummets 5.06% Intraday Following Securities Fraud Class Action Filing

Stock Track
·
Mar 04

Rosen Law Firm Files Securities Class Action Against Corcept Therapeutics

Reuters
·
Mar 03

Rosen Law Firm Urges Corcept Investors to Seek Counsel Before April 21 Lead Plaintiff Deadline

Reuters
·
Feb 28

Portnoy Law Firm Files Class Action Against Corcept Therapeutics

Reuters
·
Feb 27

Robbins LLP Alerts Corcept Investors to Lead Plaintiff Deadline in Class Action Lawsuit

Reuters
·
Feb 26

Lead Plaintiff Deadline Set in Corcept Therapeutics Securities Class Action

Reuters
·
Feb 26

Stock Track | Corcept Therapeutics Plummets 5.15% Intraday Following Analyst Price Target Cuts

Stock Track
·
Feb 26

Corcept Therapeutics Inc : Piper Sandler Cuts Target Price to $73 From $121

THOMSON REUTERS
·
Feb 25

Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Feb 25

Corcept Therapeutics price target lowered to $60 from $67 at H.C. Wainwright

TIPRANKS
·
Feb 25

Corcept Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $60 From $67

THOMSON REUTERS
·
Feb 25

U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP

Reuters
·
Feb 25

Investors File Securities Fraud Class Action Against Corcept Therapeutics

Reuters
·
Feb 25

Corcept Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Feb 25

Stock Track | Corcept Therapeutics Plunges 5.43% After-Hours on Q4 Earnings and Revenue Misses

Stock Track
·
Feb 25

Corcept Therapeutics Posts Strong 2025 Results, Issues Optimistic Outlook

TIPRANKS
·
Feb 25

Corcept Therapeutics misses Q4 revenue expectations, net income drops 21%

Reuters
·
Feb 25